ArticleJournal of virology2003
Detailed analysis of the CD8+ T-cell response following adenovirus vaccination.
Article in Journal of virology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- Needle-Free Injection Enhances the Immunogenicity and Antitumor Efficacy of Whole-Cell Tumor Vaccines.Vaccines · 2026Article
- Recombinant adenoviruses application for cancer vaccines: from genetic design to clinical translation.Frontiers in oncology · 2026Review
- Orf virus-based vectors induce potent germinal center B cell, Tfh cell, and CD8Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Article
- COVID-19 vaccination induces distinct T-cell responses in pediatric solid organ transplant recipients and immunocompetent children.NPJ vaccines · 2024Article
- The co-delivery of adenovirus-based immune checkpoint vaccine elicits a potent anti-tumor effect in renal carcinoma.NPJ vaccines · 2023Article
- Dissecting the Protective Effect of CD8Biology · 2023Review
- Engineered antibody cytokine chimera synergizes with DNA-launched nanoparticle vaccines to potentiate melanoma suppressionFrontiers in immunology · 2023Article
- A phase I study of an adenoviral vector delivering a MUC1/CD40-ligand fusion protein in patients with advanced adenocarcinoma.Nature communications · 2022Article
- The use of adenoviral vectors in gene therapy and vaccine approaches.Genetics and molecular biology · 2022Article
- Role of Adenoviruses in Cancer Therapy.Frontiers in oncology · 2022Review
- Understanding Post Entry Sorting of Adenovirus Capsids; A Chance to Change Vaccine Vector Properties.Viruses · 2021Review
- Nonreplicating Adenoviral Vectors: Improving Tropism and Delivery of Cancer Gene Therapy.Cancers · 2021Review
- Oncolytic Rhabdovirus Vaccine Boosts Chimeric Anti-DEC205 Priming for Effective Cancer Immunotherapy.Molecular therapy oncolytics · 2020Article
- Targeting Antigen to the Surface of EVs Improves theMolecular therapy. Methods & clinical development · 2020Article
- Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines.Frontiers in immunology · 2020Review
- A PBMC-Based System to Assess Human T Cell Responses to Influenza Vaccine Candidates In Vitro.Vaccines · 2019Article
- Modified MHC Class II-Associated Invariant Chain Induces Increased Antibody Responses againstJournal of immunology (Baltimore, Md. : 1950) · 2019Article
- Vaccine-Induced Skewing of T Cell Responses Protects Against Chikungunya Virus Disease.Frontiers in immunology · 2019Article
- IL-1β as mucosal vaccine adjuvant: the specific induction of tissue-resident memory T cells improves the heterosubtypic immunity against influenza A viruses.Mucosal immunology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We examined CD8(+) T-cell expansion and function following intramuscular immunization with a recombinant adenovirus. This study has identified a number of properties which may explain the strong immunogenicity of adenovirus vectors: (i) the ability to deliver large amounts of antigen into the lymphoid tissues, (ii) the ability to induce rapid expansion and migration of CD8(+) T cells throughout the lymphatics, and (iii) the ability to produce a sustained, high-level CD8(+) T-cell response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.